Skip to content
MaaT Pharma

microbiota gut

  • About us
    • Key figures
    • Our vision
    • Governance
    • Our CSR objectives
    • Membership
  • Platform
    • Microbiome Ecosystem Therapies
    • MET-N
    • MET-C
    • gutPrint®
    • cGMP manufacturing facility
  • Pipeline
    • Overview
    • Xervyteg®
    • MaaT033
    • MaaT034
    • MaaT03X
    • Scientific Publications
  • Patients & HCPs
    • Healthcare professionals (HCPs)
    • Hemato-Oncology
    • Immuno-Oncology
    • Frequently Asked Questions
  • News
    • Corporate profile
    • Press Releases
    • Media Coverage
    • Posters
    • Videos
  • Investors
    • Stock information
    • Events & Presentations
    • Regulated information
    • Shareholders Meetings
    • CSR
  • Careers
    • Our values
    • Meet our people

Tag: IR

September 4, 2024: MaaT Pharma To Present and Participate in Investor and Medical Conferences in September

MaaT Pharma To Present and Participate in Investor and Medical Conferences in September Lyon, France, September 4, 2024 – 7:30am CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, announced that [...]
  • English